中国组织工程研究
中國組織工程研究
중국조직공정연구
Journal of Clinical Rehabilitative Tissue Engineering Research
2015年
5期
778-782
,共5页
实验动物%移植%角膜移植%排斥反应%转化生长因子β1%肿瘤坏死因子α
實驗動物%移植%角膜移植%排斥反應%轉化生長因子β1%腫瘤壞死因子α
실험동물%이식%각막이식%배척반응%전화생장인자β1%종류배사인자α
Corneal Transplantation%Graft Rejection%Transforming Growth Factor beta1%Tumor Necrosis Factor-alpha
背景：同种异体角膜移植是目前治疗角膜盲最有效的方法。然而角膜移植排斥反应的发生率居高不下，研制高效低毒的免疫抑制药物是亟待解决的问题。
<br> 目的：建立角膜移植大鼠模型，在植片急性排斥期，检测空白对照组和使用转化生长因子β1滴眼液植片组的肿瘤坏死因子α的表达。
<br> 方法：建立同种异体穿透性角膜移植模型大鼠，随机分为空白对照组；1%环孢素A滴眼组(环孢素A组)；转化生长因子β1滴眼组(转化生长因子β1组)，从术后第1天开始用药，1滴/次，3次/d；术后所有受大鼠术眼点0.3%氧氟沙星滴眼液、0.5%托品酰胺滴眼液，3次/d，第12天停药。取角膜植片行苏木精-伊红染色以及免疫组织化学染色(SABC法)检测角膜植片中肿瘤坏死因子α在各组角膜组织的表达及分布情况。
<br> 结果与结论：苏木精-伊红染色显示：空白对照组植片显著增厚，大量单核细胞和淋巴细胞浸润，转化生长因子β1滴眼液组角膜植片厚度正常，无明显炎性细胞浸润。免疫组织化学显性：转化生长因子β1滴眼液组的植片肿瘤坏死因子α阳性细胞数量均较空白对照组减少(P <0.05)。提示转化生长因子β1滴眼液可减少角膜移植模型大鼠急性排斥期植片中肿瘤坏死因子α蛋白的表达，而且可以减少炎症细胞对角膜植片的浸润，这可能就是转化生长因子β1抗排斥的主要机制之一。
揹景：同種異體角膜移植是目前治療角膜盲最有效的方法。然而角膜移植排斥反應的髮生率居高不下，研製高效低毒的免疫抑製藥物是亟待解決的問題。
<br> 目的：建立角膜移植大鼠模型，在植片急性排斥期，檢測空白對照組和使用轉化生長因子β1滴眼液植片組的腫瘤壞死因子α的錶達。
<br> 方法：建立同種異體穿透性角膜移植模型大鼠，隨機分為空白對照組；1%環孢素A滴眼組(環孢素A組)；轉化生長因子β1滴眼組(轉化生長因子β1組)，從術後第1天開始用藥，1滴/次，3次/d；術後所有受大鼠術眼點0.3%氧氟沙星滴眼液、0.5%託品酰胺滴眼液，3次/d，第12天停藥。取角膜植片行囌木精-伊紅染色以及免疫組織化學染色(SABC法)檢測角膜植片中腫瘤壞死因子α在各組角膜組織的錶達及分佈情況。
<br> 結果與結論：囌木精-伊紅染色顯示：空白對照組植片顯著增厚，大量單覈細胞和淋巴細胞浸潤，轉化生長因子β1滴眼液組角膜植片厚度正常，無明顯炎性細胞浸潤。免疫組織化學顯性：轉化生長因子β1滴眼液組的植片腫瘤壞死因子α暘性細胞數量均較空白對照組減少(P <0.05)。提示轉化生長因子β1滴眼液可減少角膜移植模型大鼠急性排斥期植片中腫瘤壞死因子α蛋白的錶達，而且可以減少炎癥細胞對角膜植片的浸潤，這可能就是轉化生長因子β1抗排斥的主要機製之一。
배경：동충이체각막이식시목전치료각막맹최유효적방법。연이각막이식배척반응적발생솔거고불하，연제고효저독적면역억제약물시극대해결적문제。
<br> 목적：건립각막이식대서모형，재식편급성배척기，검측공백대조조화사용전화생장인자β1적안액식편조적종류배사인자α적표체。
<br> 방법：건립동충이체천투성각막이식모형대서，수궤분위공백대조조；1%배포소A적안조(배포소A조)；전화생장인자β1적안조(전화생장인자β1조)，종술후제1천개시용약，1적/차，3차/d；술후소유수대서술안점0.3%양불사성적안액、0.5%탁품선알적안액，3차/d，제12천정약。취각막식편행소목정-이홍염색이급면역조직화학염색(SABC법)검측각막식편중종류배사인자α재각조각막조직적표체급분포정황。
<br> 결과여결론：소목정-이홍염색현시：공백대조조식편현저증후，대량단핵세포화림파세포침윤，전화생장인자β1적안액조각막식편후도정상，무명현염성세포침윤。면역조직화학현성：전화생장인자β1적안액조적식편종류배사인자α양성세포수량균교공백대조조감소(P <0.05)。제시전화생장인자β1적안액가감소각막이식모형대서급성배척기식편중종류배사인자α단백적표체，이차가이감소염증세포대각막식편적침윤，저가능취시전화생장인자β1항배척적주요궤제지일。
BACKGROUND:Al ogeneic penetrating keratoplasty is the most effective method for treating corneal blindness. However, the incidence of rejections is high after keratoplasty, so it is urgent to develop an immunosuppressive drug with high efficacy and low toxicity. OBJECTIVE:To establish al ogeneic penetrating keratoplasty models and monitor the expression of tumor necrosis factor-αin blank control group and after transforming growth factor-β1 eyedrop during acute rejection period of corneal grafts. METHODS:Al ogeneic penetrating keratoplasty models were established and were randomly divided into blank control group, ciclosporin A group (1%ciclosporin A), and transforming growth factor-β1 group (1μg/ml transforming growth factor-β1 eyedrop). The medications from each group commenced at 1 day after surgery, one eyedrop once, three eyedrops per day. Al the operated eyes were given 0.3%ofloxacin ophthalmic solutions and 0.5%tropicaide ophthalmic solution, three times per day, for 12 days. The corneal grafts were harvested for hematoxylin-eosin staining and immunihistochemical staining (SABC method), to detect tumor necrosis factor-αexpression in corneal grafts. RESULTS AND CONCLUSION:Hematoxylin-eosin staining showed that, corneal grafts were significantly thickened, a large number of histoleucocytes and lymphocytes infiltrated in the blank control group;corneal grafts showed normal thickness and no inflammatory cel s infiltrated in the transforming growth factor-β1 group. Immunohistochemical staining showed that, there were less cel s positive for tumor necrosis factor-αin the transforming growth factor-β1 group compared with the blank control group (P<0.05). Transforming growth factor-β1 eyedrops can reduce the expression of tumor necrosis factor-αin the corneal grafts during acute rejection period, and reduce the inflammatory cel s infiltration in the corneal grafts, which is probably the mechanism of transforming growth factor-β1 to prevent and treat corneal al ograft rejection.
